One might surmise that by the time FDA asks an advisory committee to vet an application, the questions would deal primarily with clinical utility.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
